10.4 Myocardial Viability Imaging

10.4 Myocardial Viability Imaging

Why Viability Matters

In patients with ischemic cardiomyopathy and reduced left ventricular (LV) function, the critical clinical question is whether dysfunctional myocardium is hibernating (chronically underperfused but viable and capable of recovery) or scarred (irreversibly necrotic). Hibernating myocardium is metabolically active tissue that has down-regulated contractility to match reduced blood supply; if blood flow is restored by revascularization (CABG or PCI), contractile function often improves. Scar tissue will not recover regardless of revascularization. Because revascularization carries real procedural risk, viability imaging is used to triage patients toward intervention versus continued medical therapy or transplant evaluation.

The economic and survival stakes are significant. Pooled data from FDG PET and SPECT viability studies show that patients with demonstrable viable myocardium derive a survival benefit from revascularization, whereas patients with predominantly non-viable myocardium do not and may be harmed by unnecessary intervention.

F-18 FDG PET: The Reference Standard

F-18 fluorodeoxyglucose (FDG) PET is the most accurate non-invasive viability test. Its principle exploits the plasticity of myocardial metabolism. Normally, the heart preferentially oxidizes free fatty acids. When blood flow (and thus oxygen delivery) is diminished, viable cardiomyocytes shift to anaerobic glucose metabolism as a survival strategy. FDG, a glucose analog, is taken up by these viable but ischemic cells.

A combined perfusion-plus-metabolism study yields three classic patterns:

The mismatch pattern (reduced perfusion with preserved metabolism) is the hallmark of hibernating, recoverable myocardium and is the most predictive of functional recovery after revascularization.

Patient Preparation for FDG Viability

Accurate FDG viability imaging depends on forcing the myocardium onto glucose so that viable tissue conspicuously accumulates FDG while scarred tissue does not.

1. Fasting (typically 6–12 hours) lowers plasma insulin and suppresses myocardial glucose uptake, shifting the heart toward fatty-acid oxidation.
2. Glucose loading (oral glucose drink, typically 25–75 g) raises blood glucose and stimulates insulin release.
3. Insulin administration (intravenous, titrated to blood glucose) drives FDG into viable cardiomyocytes. Diabetic patients require careful, individualized insulin protocols with frequent glucose checks to avoid hypoglycemia.
4. Some protocols use a hyperinsulinemic-euglycemic clamp to standardize uptake.

Patients are imaged 45–60 minutes after FDG injection. A perfusion tracer (N-13 ammonia or Rb-82 for PET, or a same-day Tc-99m SPECT perfusion study for a hybrid approach) provides the perfusion map for the mismatch comparison.

SPECT Viability Alternatives

Not every institution has on-site PET, so several SPECT techniques assess viability with reasonable accuracy.

Tl-201 Rest-Redistribution

Thallium-201 is a potassium analog whose uptake reflects cell-membrane integrity and thus viability. The rest-redistribution protocol images the patient immediately after Tl-201 injection and again after delayed redistribution (typically 3–4 hours, sometimes 24 hours). Myocardial segments that show delayed redistribution uptake retain viable myocytes. Pooled analyses report sensitivity of roughly 80–90% but more modest specificity (54–80%) for predicting functional recovery, because delayed thallium uptake can over-predict recovery in some scarred segments. A stress-redistribution-reinjection variant adds a small reinjected thallium dose after redistribution imaging to unmask viability in segments that appeared fixed on stress-redistribution alone.

Nitrate-Augmented Tc-99m Sestamibi/Tetrofosmin

Tc-99m sestamibi uptake depends on mitochondrial membrane potential and thus reflects viability, but resting sestamibi underestimates viability, particularly in severe LV dysfunction, because it tracks perfusion as well as membrane integrity. Administering sublingual nitroglycerin (or intravenous nitrate) before rest imaging augments regional blood flow to hibernating segments, improving the detection of viable myocardium. Nitrate-augmented sestamibi performs comparably to Tl-201 rest-redistribution for predicting post-revascularization recovery.

Low-Dose Dobutamine and Contractile Reserve

Low-dose dobutamine stress (typically with echocardiography or gated SPECT) tests contractile reserve: viable but hibernating myocardium often augments contractility at low dobutamine doses (improvement in wall motion), then worsens at higher doses (biphasic response). This functional complement to metabolic imaging adds specificity to the viability assessment.

Clinical Decision Framework

The viability report should integrate perfusion, metabolism (or redistribution), and contractile reserve into a clear recommendation.

flowchart TD
    A[Ischemic cardiomyopathy + reduced LV function] --> B[Viability imaging: FDG PET or SPECT]
    B --> C{Significant viable myocardium?}
    C -->|Yes, mismatch / redistribution uptake| D[Revascularization likely to recover function]
    C -->|No, matched defect / scar| E[Medical therapy / transplant evaluation]
    D --> F[Reassess LV function 3-6 months after revascularization]

Functional recovery after revascularization may take up to 6 months, so early post-procedure imaging should not be used to declare viability assessment a failure. The technologist's role is precise, reproducible acquisition and, for FDG, rigorous glucose/insulin protocol adherence, since preparation errors are the most common cause of non-diagnostic viability studies.